GAS Journal of Clinical Medicine and Medical Research (GASJCMMR)

Volume 1, Issue 1, 2024 Journal Homepage: https://gaspublishers.com/gasjcmmr/ ISSN: 3049-1568
Email: gaspublishers@gmail.com

Efficacy of Microbiome Modulation and Immunoprophylaxis in Preventing Recurrent Urinary Tract Infections: A Systematic Evaluation of Non-Antibiotic Strategies

Iyama Anslem Chester

Department of Surgery, Urology Unit, Rivers State University, Port Harcourt, Rivers State, Nigeria

Received: 01.12.2024 | **Accepted:** 05.12.2024 | **Published:** 07.12.2024

***Corresponding Author:** Iyama Anslem Chester

DOI: *10.5281/zenodo.19633218*

Abstract **Original Research Article**

Recurrent urinary tract infections (rUTIs) constitute a severe clinical burden, especially for women, and are usually managed using prolonged or repeated antibiotic therapy. Such treatment instigates an antimicrobial resistance as well as disrupts host microbial milieu. A diverse number of non-antibiotic therapies such as microbiome modulation and immunoprophylaxis have emerged as potential alternatives. This study gathers evidence from randomized controlled trials (RCTs), meta-analyses, and translational studies looking into probiotics, vaccines, and microbiome-targeted therapies in the treatment of urinary tract infections(rUTIs). The effects of probiotic therapies are modest with recurrence decreases from 30% to 50% at controlled trials and may vary by strain and the approach for delivery. Immunoprophylaxis (specifically, oral bacterial vaccines MV140) with longer recurrence effects were significantly more likely and sustained protection was observed over several years. Microbiome-targeted therapies, such as fecal microbiota transplantation (FMT), present promising preliminary data but are still still to be explored. Clinical translation should be extended with integrated approaches.

Keywords: recurrent urinary tract infections, microbiome modulation, immunoprophylaxis, probiotics therapy, antimicrobial resistance.

Introduction

Recurrent urinary tract infections (rUTIs) are a common practice clinical problem which affects about 20-30% of women once their first infections have occurred and in a significant way significantly affects the quality of life [1]. With two or more infections within six months or three or more within one year, rUTIs are associated with repeated healthcare and a significant economic burden. Even more uropathogens such as Klebsiella, Proteus and Enterococcus, whose most popular pathogens are found to be linked with persistent gastrointestinal tract infections [4]. General management is heavily dependent on antibiotic prophylaxis or as required by either ongoing management or post coitmentary management. This approaches are effective at decreasing rates of recurrence, but add some important challenges; multidrug resistance is selected and the commensal microbiota cannot survive [2]. The increasing global threat of antimicrobial resistance has made more pressing research possible regarding their role in rUTI pathogenesis. These discoveries have ignited the development of two leading non-antibiotic strategies - microbiome modulation and immunoprophylaxis. Isolated in terms of protection against uropathogens, microbiome.

Methods:

This study synthesizes evidence from randomized controlled trials (RCTs), meta-analyses, and translational studies evaluating probiotics, vaccines,

and microbiome-targeted therapies in rUTI prevention. Emphasis is placed on recurrence rates, duration of protection, and mechanistic plausibility.

Pathophysiology of rUTIs: The Microbiome Immune Axis

Historically, the urinary tract was considered sterile. Advances in sequencing technologies have refuted this paradigm, revealing a complex urinary microbiome that interacts dynamically with vaginal and gut microbial ecosystems [3].

Vaginal Microbiome and UTI Susceptibility

A key protective mechanism of colonization rupiaviruses is the vaginal microbiome. Lactobacillus species (primarily L. crispatus) - producing acidic solutions [3]. The acidic environment we create is adverse to pathogenic organisms. After antibiotics or hormonal changes, the reduction in the number of Lactobacillus in an environment is characteristic of dysbiosis and more infection (the combination of vaginal, or vaginal), including low Lactobacillus species presence [4]. Clinical data has shown that in women with rUTIs, the vaginal Lactobacillus concentration falls and the uropathogens more colonize them [4].

Gut Bladder Axis

It is a reservoir for uropathogens in the gastrointestinal tract. Uropathogenic E. coli intestinal colonization allows them to access the periurethral and ultimately enter the urinary tract [5]. Antibiotic use that disrupts gut microbiota, especially via repeated antibiotic applications, makes it more resistant and maintains recurrence cycles. This gut bladder axis offers mechanistic basis for microbiome-targeted therapies.

Host Immune Response

Host immune defenses, including innate and adaptive responses, play a critical role in infection control. However, recurrent infections may reflect inadequate immune memory or evasion strategies employed by pathogens. Intracellular bacterial reservoirs and biofilm formation further complicate eradication [4].

Microbiome Modulation Strategies

Probiotics

Probiotics, particularly Lactobacillus species, represent the most extensively studied microbiome-based intervention.

Clinical Evidence

A landmark randomized controlled trial of Stapleton et al. revealed recurrence to be significantly reduced in intravaginal administration of Lactobacillus crispatus to the placebo [6]. The similar conclusion was supported by Beerepoot et al. found that oral probiotics in the context of antibiotic prophylaxis were not in direct connection with recurrence and in that they produced less adverse effects [7]. Specifically, new study including combined oral and vaginal administration have led to 50% reduction of recurrence and delayed time to infection [7].

Mechanisms of Action

Probiotics exert protective effects through multiple mechanisms:

- Competitive inhibition of uropathogen adhesion
- Production of antimicrobial compounds
- Modulation of mucosal immune responses

Limitations

Although there are potential clinical trials for probiotics, the efficacy of probiotics is variable. The interpretability of the experimental results is compromised by differences in strain, dosing and delivery route. Several systematic reviews emphasize the lack of standardized protocol and non-reliable long-term data [8].

Fecal Microbiota Transplantation and Emerging Therapies

Fecal Microbiota Transplantation and Emerging Therapies (FMT) has gained attention as a means of restoring gut microbial diversity.

Evidence Base

Observational studies indicate significant reductions in UTI frequency following FMT, particularly in patients with multidrug-resistant infections [9]. In some cohorts, recurrence rates decreased by more than 70%.

Mechanistic Rationale

Fecal Microbiota Transplantation and Emerging Therapies(FMT) restores microbial diversity, suppresses pathogenic colonization, and reduces antibiotic-resistant reservoirs [10].

Limitations

Evidence remains preliminary, with a lack of randomized trials and regulatory approval for UTI indications.

Immunoprophylaxis

Vaccine Strategies: The objective of vaccines for uropathogens is to drive mucosal and systemic immunity [11]. Unlike conventional vaccines which prevent recurrence at high rates of infection (RR 1.52, RR 13, RR 13), the present oral vaccine MV140 has been of high evidence proving a lot beneficial: sustained protection for several years with some 50% of patients still infected [12].

Mechanisms: Vaccines promote the immune system via both innate and adaptive immunity, producing novel pathogen recognition and clearing. Mucosal immunity is crucial in the outbreak, because it is located in the site of the infection.

Advantages and Challenges: There are several advantages of vaccines:

- The ability to sustain longevity
- A reduction in dependence on antibiotics
- The potential of population-level impact but obstacles include:
- Very limited availability
- Variability in pathogen coverage
- Key to large-scale validation

Comparative Analysis

Microbiome modulation and immunoprophylaxis differ fundamentally in their mechanisms and outcomes.

- Probiotics: Moderate efficacy, require continuous use
- FMT: High potential, limited evidence
- Vaccines: Durable protection, strongest long-term data

Vaccines appear to offer the most sustainable solution, though integration with microbiome strategies may enhance outcomes.

Discussion

The central question whether non-antibiotic treatments can consistently reduce rUTI recurrence can be firmly answered in the affirmative. Evidence suggests that modulation of the microbiome and immunoprophylaxis at once contribute to reduced recurrence rates, but sustainability of recurrence will vary based on host variation and environmental factors. Vaccines, on the other hand, serve to promote targeted, durable immune responses. One strategy may be the most appropriate, for example, re-balancing microbiome balance can promote the immune response of the vaccine by optimizing mucosal immune activity.

Research gaps and future direction: There are several challenges still identified in this study:

1. Not standardized antibiotics
2. Few continuous long-term RCTs
3. Minimal implementation of microbiome sequencing in clinical trials
4. Implications for the development of precision medicine frameworks including microbiome profiling, immunological markers and patient stratification. In the future, study will be centered on techniques to integrate microbiome profiling, immunological markers, and symptom classification into the clinical framework.

Conclusion

Non-antibiotic strategies, particularly vaccines and probiotics, represent viable approaches to reducing

rUTI recurrence. Vaccines offer the most durable protection, while microbiome modulation provides important adjunctive benefits.

Although these strategies cannot yet fully replace antibiotics, they represent a critical step toward sustainable, resistance-conscious management of rUTIs.

References

1. Foxman B. Nat Rev Urol. 2010;7:653–660.
2. Gupta K, et al. Clin Infect Dis. 2011;52:e103–e120.
3. Stapleton AE. Microbiol Spectr. 2016;4.
4. Flores-Mireles AL, et al. Nat Rev Microbiol. 2015;13:269–284.
5. Magruder M, et al. mBio. 2019;10:e00279-19.
6. Stapleton AE, et al. Clin Infect Dis. 2011;52:1212–1217.
7. Beerepoot MAJ, et al. Clin Infect Dis. 2012;54:345–352.
8. Grin PM, et al. J Urol. 2013;190:1981–1989.
9. Tariq R, et al. Open Forum Infect Dis. 2017;4:ofw256.
10. Wang J, et al. Front Microbiol. 2020;11:120.
11. Lorenzo-Gómez MF, et al. Urol Int. 2015;94:1–9.
12. Angulo JC, et al. Eur Urol Focus. 2022;8:712–718.